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linergic medications. The highest prevalence was seen for Level 1 medications 
(52.37%) followed by Level 2 (3.02%) and Level 3 (2.31%) medications. The preva-
lence of concurrent use of anticholinergic medications of various levels was 8.42% 
(7.53–9.32). Multinomial regression analysis revealed that predisposing (age) and need 
(behavioral symptoms, activities of daily living, out of bed mobility and depression) 
factors were positively associated with Level 1 drug use. Need factors (behavioral 
symptoms and total number of medications taken) were found to be negatively associ-
ated with Level 2 drug use whereas need factors like parkinsonism and depression 
were positively associated with receiving Level 3 medications and concurrent use, 
respectively. CONCLUSIONS: Nearly three of four elderly nursing home residents 
with dementia received anticholinergic medications of different levels. The ﬁndings 
suggest that there is a need to optimize anticholinergic medications in dementia 
patients, especially the higher level agents due to their signiﬁcant adverse proﬁle in 
dementia patients.
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OBJECTIVES: Individuals with a serious mental illness (SMI) often experience recidi-
vistic patterns in the criminal justice system (CJS). It has been argued that the provision 
of mental health services can disrupt this pattern. We examined the impact of com-
munity based mental health services on the arrest patterns of adults with a SMI who 
became involved in the CJS in Pinellas County Florida and Harris County Texas. 
METHODS: We identiﬁed adults 18–64 years old in Florida and Texas with a SMI 
who spent at least one day in jail during an index year. Statewide and local administra-
tive data sets were used to document their patterns of arrests and utilization of health 
and mental health services over 3–4 year periods. Generalized estimating equations 
were used for count data to estimate the association of outpatient and ER/inpatient 
mental health contacts in a quarter and arrests in the subsequent quarter. Individual 
ﬁxed effects models were also estimated to account for unobserved time invariant 
factors correlated with treatment and the likelihood of arrest. RESULTS: We identiﬁed 
3769 and 8505 individuals in the Florida and Texas data sets respectively. In Florida, 
individuals receiving outpatient services in a quarter were 20% less likely to be 
arrested in the subsequent quarter. The effect was greater for misdemeanor than for 
felony arrests. Individuals receiving ER/inpatient services were 7% more likely to be 
arrested in the subsequent quarter, and 13% more likely to have a felony arrest. The 
association between outpatient mental health services and arrests was conﬁrmed by 
the individual ﬁxed effects model. Parallel analyses are underway using Texas data to 
determine if the relationships hold for different jurisdictions and time frames. 
CONCLUSIONS: Outpatient mental health services were associated with a decrease 
in the risk of arrests among groups of individuals with a SMI and criminal justice 
involvements.
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OBJECTIVES: Optimal treatment of major depressive disorder (MDD) includes the 
selection of an adequate antidepressant medication and its delivery at a fully thera-
peutic dose for adequate treatment duration. Many factors may inﬂuence a physician’s 
decision making with respect to antidepressant choice and appropriate dose level. This 
study examined the pretreatment predictors of high-dose prescription of duloxetine 
for MDD patients in the real world clinical setting. METHODS: In a large commercial 
managed-care claims database, 6,132 MDD patients, who were initiated on duloxetine 
between July 1, 2005 and June 30, 2006, had no prior prescription of duloxetine for 
6 months, and had continuous enrollment for both 12 months prior to and post initia-
tion, were included. The associations between demographics and pre-initiation clinical 
variables and the maximum prescribed duloxetine dose (high: > 60 mg/day; mid: 
60 mg/day) were examined by chi-square tests and logistic regression. RESULTS: Of 
the sample, 16.3% had a maximum prescribed duloxetine dose of less than 60 mg/
day; 59.3%, 60 mg/day; and 24.4%, >60 mg/day. Compared with mid-dose patients, 
high-dose patients were older; had more comorbidities of neuropathic pain, osteoar-
thritis, ﬁbromyalgia, drug dependence, and bipolar disorders; were more likely to be 
treated by psychiatrists; used more benzodiazepines, venlafaxine, atypical antipsychot-
ics, psychostimulants, and anticonvulsants; and had higher pharmacy and medical 
costs in the prior 1 year (All p values < .05). After adjustment for health plan type 
and geographic region of residence, the following factors were independently associ-
ated with high-dose prescription: older age (36–64 vs. 18–35 years, OR = 1.34–1.53), 
neuropathic pain (OR = 1.56), prior use of psychostimulants (OR = 1.32), benzodi-
azepines (OR = 1.22), venlafaxine (OR = 1.24), atypical antipsychotics (OR = 1.35), 
and physician specialty (psychiatrist vs. non-psychiatrist, OR = 1.54). CONCLU-
SIONS: Multiple demographic and clinical characteristics and prior costs are associ-
ated with a high-dose duloxetine prescription. High-dose treated patients may 
represent a group of complicated patients with high medical costs who need intensive 
treatment.
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OBJECTIVES: Bipolar disorder (BD) treatment guidelines state that antidepressants 
(ADs) may precipitate, or exacerbate manic or mixed episodes and generally recom-
mend tapering or discontinuing ADs for patients with recent acute manic or mixed 
episodes. This study assessed the association between continued AD use and BD-
related re-hospitalizations among BD patients. METHODS: Using the PharMetrics 
Patient-Centric Database from January 1, 2004–June 30, 2007, we identiﬁed adults 
with an acute psychiatric event (“index event”), deﬁned by hospitalizations, emergency 
room visits, or physician visits with a prescription for a new BD medication with a 
primary diagnosis of BD I mania or BD I mixed. All patients were required to be 
eligible for the 12 months before and after index event and have a BD-related hospi-
talization (any diagnosis of any BD subtype) in the pre-index period. Patients with 
schizophrenia at any time during the study period were excluded. Continued AD use 
was deﬁned using prescription drug claims as 30+ days of available AD therapy within 
120 days after the index event. Logistic regression—controlling for age, sex, geo-
graphic region, baseline comorbidities—was used to determine the association 
between continued AD use and post-index BD-related re-hospitalizations (any diag-
nosis of any BD subtype). RESULTS: A total of 2126 patients met study criteria (mean 
age, 44; 57% female). 433 BD patients (20.4%) were re-hospitalized within 1 year. 
Patients receiving continued AD therapy (31.5%) were signiﬁcantly more likely to be 
re-hospitalized (OR, 1.387; 95% CI, 1.102, 1.748) than those without continued use. 
Other predictors of increased risk of re-hospitalization included being female and 
baseline diagnoses of comorbid substance abuse and eating disorders. CONCLU-
SIONS: Continued AD use in manic or mixed BD may be inappropriate. In this study, 
AD use for 30+ days within 120 days after an acute episode was associated with 
greater risk of BD-related re-hospitalization.
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OBJECTIVES: To evaluate risk and predictors of hospitalization among commercially 
insured patients with bipolar I disorder. METHODS: Retrospective cohort analysis 
using the PharMetrics Patient-centric Database, including patients with ≥1 inpatient 
or ≥2 outpatient medical claims indicating bipolar I disorder and ≥1 prescription for 
an antipsychotic medication between 7/1/2005, and 3/31/2007. Patients were followed 
1 year from date of ﬁrst (index) antipsychotic prescription. Continuous health beneﬁt 
eligibility from 1 year before (baseline) through 1 year after (follow-up) index was 
required. Patients had to receive ≥1 additional antipsychotic claim during follow-up 
to ensure a treated population. Adherence was measured using medication possession 
ratio (number of outpatient-treated days divided by total number of outpatient days 
during follow-up). Multivariate logistic regressions were used to identify factors asso-
ciated with all-cause (AC) and psychiatric-related (PR) hospitalization. RESULTS: A 
total of 12,100 patients were eligible. Mean (±SD) patient age was 37.2 (±15.7) years, 
59.9% were female; 22.8% had baseline diagnoses of substance abuse, and 49.8% 
had other psychiatric conditions. During follow-up, 27.9% of patients had AC and 
25.3% had PR hospitalizations. On average (±SD), patients had 0.5 (±1.1) AC and 
0.4 (±1.0) PR hospitalizations. Baseline substance abuse or diagnosis of other psycho-
sis; use of antidepressants, anxiolytics, or anticholinergics; psychiatric hospitalization; 
and nonadherence to antipsychotic therapy during follow-up were associated with 
signiﬁcantly greater risk (P < 0.05) of AC and PR hospitalizations; age < 35 years was 
also associated with signiﬁcantly greater risk of PR hospitalization. Baseline anticon-
vulsant use was associated with signiﬁcantly lower risk of PR hospitalization. CON-
CLUSIONS: Several patient characteristics appeared to be associated with greater risk 
of hospitalization among commercially insured bipolar I patients receiving antipsy-
chotics. These ﬁndings may be useful to health plan administrators interested in tar-
geted interventions, though further research on the impact of such interventions is 
needed. Supported by funding from Ortho-McNeil Janssen Scientiﬁc Affairs, LLC.
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OBJECTIVES: Compare transitions between mild, moderate and severe health states, 
and to death or institutionalization for Alzheimer disease (AD) and non-AD dementia 
patients. METHODS: The National Alzheimer Coordinating Center’s Uniform Data 
Set (NACC-UDS) is a large, longitudinal dataset funded by the National Institute of 
Aging that includes AD and non-AD dementia patients, and non-demented controls. 
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Using the mini-mental state examination (MMSE) we classiﬁed patients as mild 
(27–20), moderate (19–10) or severe (<10). We calculated the association between 
previous and current MMSE stage and the association between previous MMSE stage 
and institutionalization using multinomial logistic models with random effects to 
account for individual and center level correlation, controlling for demographic char-
acteristics and time since last observation. The coefﬁcients from the regressions were 
used to calculate predicted probabilities using the population means for each of the 
covariates. RESULTS: Our analysis was limited to 3,418 patients with dementia 
(52.3% probable AD) and two or more observations with complete data for our 
covariates of interest. Average baseline age was 76.72 years old. Average MMSE was 
17.05. The majority were female, 50.4%. The regression coefﬁcient for the previous 
MMSE stage was signiﬁcant in all cases and suggests that being in a higher MMSE 
stage at the previous visit is associated with being in a higher MMSE stage or dead. 
Previous MMSE stage was found to be strongly associated with institutionalization. 
White, non-Hispanic, unmarried patients were more likely to be institutionalized, all 
else equal. Patients with non-AD dementia were more likely to be institutionalized 
than patients with AD. CONCLUSIONS: Patients with AD in the NACC -UDS 
database transition more quickly to more severe stages of MMSE than non-AD 
dementia patients. Non-AD dementia patients are more likely to transition to institu-
tionalization and die than patients with AD.
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OBJECTIVES: The purpose of this analysis was to estimate the impact of escitalopram 
(generic drug) reimbursement on the budget of the National Health Fund (NHF) in 
Poland. METHODS: The budget impact analysis was prepared for 5 years time 
horizon (2009–2013) from the public payer’s as well as patient’s perspective. Two 
scenarios were compared: present—without reimbursement of generic version of esci-
talopram and proposed—placing of escitalopram on the list of reimbursed drugs in 
Poland. It was assumed that escitalopram will take over a part of market of selective 
serotonin reuptake inhibitors (SSRIs) and selective serotonin-noradrenergic reuptake 
inhibitors (SNRIs). The analysis was performed in two variants: basic analysis, assum-
ing new reimbursement limit for escitalopram which equals the retail price of generic 
escitalopram and alternative variant presuming equal reimbursement limits for esci-
talopram and venlafaxine. Additionally, the minimum and maximum case scenarios 
and one-way sensitivity analyses were performed. RESULTS: Assuming the reimburse-
ment of generic escitalopram in basic variant, the annual expenses from the budget 
of the NHF for major depressive disorder treatment would rise from 344,723 PLN in 
ﬁrst year to 5,770,153 PLN in ﬁfth year in comparison to present scenario. In alterna-
tive variant, the estimated expenses would rise from 144,833 PLN in ﬁrst year to 
2,716,183 PLN in ﬁfth year. From patient’s perspective the expenses for MDD treat-
ment would decrease in basic variant from 245,874 PLN to 4,829,704 PLN and in 
alternative variant from 45,984 PLN to 1,775,734 PLN in ﬁrst and ﬁfth year, respec-
tively, in comparison to present scenario. CONCLUSIONS: Budget impact analysis 
showed that the reimbursement of generic escitalopram would increase expenses from 
the NHF’s perspective and savings from patient’s perspective.
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OBJECTIVES: Bipolar disorder (BPD) is a debilitating recurrent chronic mental 
illness, characterized by cycling states of depression, mania, hypomania, and mixed 
episodes. The objectives of this study were to calculate national estimates of the annual 
burden of inpatient hospitalizations of children and adolescents with bipolar disorder 
(BPD); to describe and compare the burden across various patient characteristics, 
hospital characteristics, and key comorbidities associated with BPD; and to determine 
the independent effects of these factors on hospitalization costs. METHODS: Dis-
charge observations for children whose primary diagnosis was BPD were collected 
from the Kids’ Inpatient Database (KID). The burden was estimated as total number 
of days in the hospital, total charges, and total costs. Mean costs and charges were 
calculated and were broken down by patient and hospital characteristics and by the 
top six comorbidities found for BPD. Ordinary–least-squares regression models 
explaining cost were estimated for both 2003 and 2006, and the models were com-
pared by way of a Chow test. RESULTS: There were 39,136 (40,679) bipolar disorder 
discharges in 2003 (2006), with total associated costs of $176 ($233) million in 2003 
(2006). The mean cost was $4,490 ($5,725), while the mean length of stay was 8.12 
(8.99) days in 2003 (2006). Factors associated with higher cost included youth 
(younger than 13), being black, being from a high-income family, having many diag-
noses, being insured by Medicaid, living in the North East or West regions of the 
country, and having a long hospital stay. CONCLUSIONS: Declining trends in mean 
cost and length of stay, documented in previous studies for children with BPD, per-
sisted into 2003 but showed a slight reversal by 2006.
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OBJECTIVES: There is accumulating evidence of sub-therapeutic dosing of second-
generation antipsychotics (SGAs), leading to suboptimal control of disease and higher 
overall treatment costs. Additional evidence is needed to better understand the clinical 
and economic outcomes of patients who receive clinically effective doses of SGAs. The 
objectives of this study were to distinguish patients receiving clinically recommended 
doses of SGAs and compare their medical care costs. METHODS: Patients with 
schizophrenia (N = 12,133) on an oral SGA (aripiprazole, olanzapine, quetiapine, 
risperidone or ziprasidone) were identiﬁed in Medicaid claims databases (2001–2008) 
from 8 states. Patients were followed for 18 months (6 month pre-index period during 
which patients did not receive an SGA, followed by a 12-month post-index utilization 
period to determine total costs). For patients on recommended dosing, costs were 
compared using a generalized linear model with a gamma distribution and log-link 
function, adjusting for baseline covariates (age, gender, race, pre-index costs, Charlson 
co-morbidity score, and speciﬁc psychiatric co-morbidities) with ziprasidone as the 
reference group. RESULTS: Of the 12,133 patients meeting study criteria 7,213 (59%) 
were taking clinically recommended doses by day 61 of their follow-up period. Patients 
on quetiapine had the lowest percentage at 37% (N = 1,057/2,869). Other results 
were aripiprazole 66%(N = 996/1515), olanzapine 65% (N = 1831/2828), risperidone 
73% (N = 2807/3821), and ziprasidone, 47% (N = 522/1,100). When comparing 
groups of patients with recommended dosing, mental health-related costs (p = 0.006) 
and all-cause costs (p = 0.0005) were statistically higher for the quetiapine group 
compared to the ziprasidone group. CONCLUSIONS: Less than two-thirds of the 
Medicaid patients with schizophrenia who were started on an SGA were taking clini-
cally recommended doses 2 months after their initial start. For patients using clinically 
recommended doses, those taking quetiapine had higher mental health-related costs 
and higher all-cause costs compared to patients taking ziprasidone.
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HEALTH CARE COSTS IN PATIENTS WITH BIPOLAR DISORDER 
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OBJECTIVES: To compare the risk of hospitalization and associated inpatient psy-
chiatric treatment costs among patients with bipolar disorder treated with aripipra-
zole, ziprasidone, olanzapine, quetiapine or risperidone. METHODS: A retrospective 
cohort study using the Pharmetrics Patient-Centric database from January 1, 2003 
-September 30, 2008 was conducted. Included patients were aged 18–64 years, diag-
nosed with bipolar disorder, and newly treated with atypical antipsychotic medica-
tions. Patients were followed from treatment initiation to psychiatric hospitalization, 
medical hospitalization, discontinuation of index medication, loss to follow-up, or 
one year. Mean length of therapy was similar among the treatment groups. General-
ized gamma regression compared inpatient costs between the groups. RESULTS: 
Among 19,176 bipolar patients, those treated with aripiprazole (n = 3,690) had a 
lower risk of hospitalization during their time on treatment (4.9%) compared to 
patients receiving ziprasidone (9.2% p < 0.001, n = 1515)), olanzapine (7.0% p < 
0.001, n = 3038)), quetiapine (7.3% p < 0.001, n = 7936), and risperidone (7.2% p 
< 0.001, n = 2997). Fewer hospitalizations translated into lower per-patient-per-
month psychiatric-related inpatient health care costs for patients receiving aripipra-
zole ($121) compared to those receiving other atypical antipsychotics (ziprasidone 
$249 p < 0.001, olanzapine ($203 p < 0.001), and quetiapine ($182 p < 0.006). Dif-
ferences in hospitalization costs were not statistically signiﬁcant between aripiprazole 
and risperidone ($159 p < 0.354). Total psychiatric-related health care costs were also 
signiﬁcantly lower among aripiprazole patients than patients in each of the other 
treatment groups (p < 0.05). CONCLUSIONS: Among patients with bipolar disorder 
and newly treated with atypical antipsychotic medications, treatment with aripipra-
zole was associated with a lower risk of psychiatric hospitalization compared to 
patients receiving other atypical antipsychotic medications and lower psychiatric-
related inpatient costs compared to patients receiving ziprasidone, quetiapine, or 
olanzapine. These data are consistent with previous published ﬁndings studying the 
Ingenix integrated claims dataset. The results of this study suggest that aripiprazole 
may offer an economic advantage over other atypical antipsychotic medications in 
this patient population.
